Compare Enveric Biosciences Inc (ENVB) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Moody's Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Moody's Corporation trades at $460 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 11682.4× Enveric Biosciences Inc's market cap, and Moody's Corporation pays a 0.9% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Moody's Corporation for 132 Days on average.
| ENVB | MCO | |
|---|---|---|
Market Cap | $6.80M | $79.44B |
Volume | 64,867 | 526,684 |
Sector | Health | Financials |
52-Week High | $10.80 | $539.61 |
52-Week Low | $1.27 | $412.23 |
Typical Hold Time | 14 Days | 132 Days |
Enterprise Value | -$1.49M | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Moody's Corporation (MCO) trades at $449.63, down 0.59% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth has accelerated from $5.5B in 2022 to $7.7B in 2025, while net income margins expanded to 34.25%. Recent developments include strategic partnerships and board appointments, supporting the company's market leadership in credit analytics.
The investment outlook is positive given Moody's robust profitability, high ROE of 80.15%, and analyst consensus price target of $536.40 (19% upside). Risks include high valuation multiples (P/E 28.53, P/S 9.79) and exposure to economic cycles affecting credit demand. Institutional sentiment remains bullish with 56% buy ratings, though technical indicators suggest near-term consolidation near support at $440.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
